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Summary Multidrug resistance (MDR) in cancer cells is a major contributor to the failure of chemotherapy
treatment. This paper describes a novel protein named the anthracycline resistance associated (ARA) protein.
The ara gene is amplified in the MDR leukaemia line CCRF-CEM/E1000 and its mRNA is overexpressed.
ARA belongs to the ATP binding cassette (ABC) family of proteins. Another ABC protein, the multidrug
resistance-associated protein (MRP), has previously been reported to be overexpressed in the CEM/E1000
subline. The primary amino acid sequence of ARA indicates that it is 49.5 kDa without glycosylation, and that
it has one potential glycosylation site. ARA has one ATP binding site and associated transmembrane regions.
This is in contrast to MRP (190 kDa, 172 kDa deglycosylated) and most other higher eukaryote ABC proteins,
which consist of two similar halves, each having one ATP binding site. In addition to ARA being coexpressed
with MRP, comparison of amino acid sequences showed that, among known proteins, ARA is most similar to
the C-terminal half of MRP.
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Drug resistance in cancer cells is known to have a number of
different forms. A major form of drug resistance has been
termed multidrug resistance (MDR), of which several types
have been reported. A general characteristic of MDR cells is
that they are resistant to a broad range of structurally
unrelated, natural product drugs. The first MDR mechanism
described in detail is attributed to overexpression of P-
glycoprotein, the product ofthe human mdrl gene (for review
see Germann et al., 1993; Nielsen and Skovsgaard, 1992). P-
glycoprotein is a plasma membrane-bound glycoprotein that
acts as an ATP-dependent drug efflux pump and is a member
of a diverse group of membrane transport proteins called the
ABC (ATP-binding cassette) protein family (for review see
Higgins, 1992). ABC proteins require two nucleotide-binding
regions and associated transmembrane regions to be
functional. Nucleotide-binding regions of ABC proteins are
characterised by conserved sequences such as the Walker A
and Walker B sites (Walker et al., 1982) and the ABC
signature site (Higgins et al., 1990). In eukaryotes, the two
sites are usually as two halves of a single polypeptide, while
in prokaryotes ABC proteins have only one nucleotide-
binding region and are therefore functional as dimers.
Another MDR mechanism involves overexpression of the
multidrug resistance-associated protein (MRP) (Cole et al.,
1992), which is also an ABC protein. MRP has been
identified as a 190 kDa glycoprotein (Barrand et al., 1994;
Krishnamachary and Center, 1993) and is reported to be
located in the plasma membrane (Flens et al., 1994; Muller et
al., 1994; Zaman et al., 1993) and in some cases the
endoplasmic reticular membrane (Krishnamachary and
Center, 1993) and endocytic vesicles (Almquist et al., 1995).
The dependence of MRP-mediated MDR on ATP has been
demonstrated (Leier et al., 1994; Versantvoort et al., 1994).
Cells expressing MRP often show reduced drug accumulation
(Davey et al., 1995; Binaschi et al., 1995; Barrand et al.,
1993) and this has been reported in a cell line transfected with
the MRP gene (Cole et al., 1994).
A number of recent reports have linked glutathione
metabolism with MRP. Drug resistance in several MRP
overexpressing lines was reversed by the addition of
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buthionine sulphoximine (BSO), an inhibitor of glutathione
synthesis (Davey et al., 1995; Gekeler et al., 1995; Schneider
et al., 1995). MRP has also been demonstrated to be a
transporter of glutathione conjugates (Jedlitschky et al., 1994;
Leier et al., 1994; Muller et al., 1994).
This paper describes a cDNA encoding a novel member of
the ABC protein family which we have named the
anthracycline resistance-associated (ARA) protein. ARA has
some similarities with MRP and is coordinately expressed
with MRP in the leukaemia MDR line CCRF-CEM/E1000
(E1000) (Davey et al., 1995). The possibilities for a role of
ARA in the MDR phenotype are discussed.
Materials and methods
Cell lines and tissue culture
The cell lines used were the human leukaemia T-cell line
CCRF-CEM (CEM) (Foley et al., 1965) and its anthracy-
cline-selected MDR subline CCRF-CEM/E1000 (E1000)
which overexpresses mrp mRNA but does not express
detectable levels of P-glycoprotein or mdrl mRNA (Davey
et al., 1995). Cell cultures were maintained as previously
described (Davey et al., 1995).
RNA extraction, cDNA library synthesis and Northern blotting
E1000 cells used to prepare a cDNA library were exposed to
epirubicin for 18 h before total RNA was extracted
(Wilkinson, 1988). Poly-A RNA was isolated using PolyA
Tract (Promega, MA, USA). A cDNA library was prepared
from 2 ,g of poly-A RNA using a Riboclone cDNA
Synthesis kit (Promega) in a lambda gtl 1 Sfi/Not vector
(Promega). The amplified library was screened by plaque
hybridisation using 32P-labelled pmrp 10.1 (Cole et al., 1992)
as probe. Conditions for screening were a 15 min prehy-
bridisation in 7% sodium dodecyl sulphate (SDS), 0.25 M
phosphate pH 7.0, 1 mM EDTA followed by overnight
hybridisation in fresh solution plus denatured probe DNA.
Washes were 1 x 5% SDS, 40 mM phosphate pH 7.0, 1 mM
EDTA and 1 x 1% SDS, 40 mm phosphate pH 7.0, 1 mM
EDTA. Hybridisation and washes were at 55°C. Positive
plaques were isolated and confirmed positive over several
screenings.ara, a novel MDR gene
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Analysis of cDNA clones
Restriction maps of positive cDNA clones were constructed
and the identified restriction sites were used to create a series of
subclones in the plasmid vector pGEM 1lZf(-) (Promega).
Nucleotide sequence was determined by the dideoxy chain
termination method (Sanger et al., 1977) using the Sequenase
Version 2.0 DNA sequencing kit (USB, Ohio, USA) and the
Stratagene Cyclist sequencing kit (Stratagene, USA). For
regions of DNA with a high GC content, nucleotide sequence
was determined using single strand DNA-binding protein
(Promega) and the Sequenase kit.
Northern blots
Total RNA for Northern blots was extracted using guanidine
thiocyanate (Chomcyznski and Sacchi, 1987). An aliquot of
20 pg of total RNA was fractionated by electrophoresis
through a 1.0% agarose gel containing 1.25% formaldehyde.
Electrophoresis, transfer to a nylon membrane (Zetaprobe,
Bio-Rad, Australia) and hybridisation at 42°C in a formamide
buffer were as described by Sambrook et al. (1989).
cells (Figure 1), confirming the absence of detectable ara
mRNA in the CEM line.
Genomic DNA analysis of the ara gene
DNA was extracted from E1000 cells and CEM cells,
digested with HindIII or XbaI and analysed by Southern
blot using an ara specific probe (Figure 2a). The size of the
hybridisation bands was the same in CEM cells and E1000
cells. Ethidium bromide staining of the gel before transfer
showed identical amounts of DNA in all lanes, and the
autoradiograph results shown in Figure 2a were all obtained
from the same exposure. The stronger signal in E1000 cells
indicates that the ara gene has been amplified in the EIOOO
subline in a similar manner to that observed for the mrp gene
in this subline (Figure 2b).
The anthracycline resistance-associated (ARA) protein
The ara cDNA sequence contains an open reading frame of
453 codons. The predicted molecular mass of the encoded
protein based on the primary amino acid sequence is 49 561
DNA extraction and Southern blotting
Genomic DNA was extracted from cells (Sambrook et al.,
1989), 10 pg of genomic DNA was digested with restriction
endonucleases and the DNA fragments fractionated on a
0.5% agarose gel in TAE buffer (Sambrook et al., 1989).
Fractionated DNA was transferred to a nylon membrane
(Zetaprobe, BioRad) and cross-linked to the membrane by
UV radiation in a Stratalinker (Stratagene). Hybridisation
was as for cDNA library screening with hybridisation and
washes at 65°C.
Results
The anthracycline resistance-associated (ara) cDNA
A cDNA library prepared from EIOOO cells was screened at
low stringency with pmrplO.1 as probe. A number of weak
positive plaques were isolated and confirmed positive by
additional screening. Partial nucleotide sequence was
obtained for several independent clones and these were
shown to originate from the same gene. The nucleotide
sequence was determined for an apparent full length cDNA
which was found to be novel by nucleotide database
comparison. The sequence contains an open reading frame
coding for a protein which has been named the anthracycline
resistance-associated (ARA) protein. The full nucleotide
sequence of the cDNA (ara) has been entered into the
EMBL nucleotide database with accession code X95715. A
number of clones differed in their 3' sequence, indicating the
use of several polyadenylation sites. Comparison of ara
sequence with the EMBL nucleotide database showed it to be
most similar to the sequence of mrp (accession code L05628).
Expression of ara
The expression of the ara gene was examined by Northern
blot analysis of mRNA under stringent conditions with a
probe consisting of the ara 3' coding and 3' untranslated
regions (Figure 1). A 2.2 kb band of mRNA was detected in
the EIOOO subline but not the parent CEM line, even after
overexposure of the autoradiograph (not shown). The size of
2.2 kb is close to the expected size based on the cDNA clones
characterised as being either full length or close to full length.
The expression of mrp was examined by hybridisation of the
same RNA samples using pmrplO.1 as probe (Figure 1). This
produced a band of 6.6 kb corresponding to the expected mrp
mRNA size reported previously in the E1000 subline (Davey
et al., 1995). The integrity of the mRNA in the samples was
determined by hybridisation with a ,B-actin probe. This gave a
discrete band ofhybridisation in RNA from CEM and EIOOO
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Figure 1 Northern blot ofmRNA from CEM (A) and E1000 (B)
cells probed with ara (a), mrp (b) and ,B-actin (c) 32P-labelled
probes. Molecular size markers are shown on the left.
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Figure 2 Southern blot analysis of genomic DNA probed with
(a) 32P-labelled ara cDNA and (b) 32P-labelled mrp cDNA. CEM
(A) and E1000 (B) genomic DNA was digested with HindIII (left
lane) and XbaI (right lane). All lanes in (a) are from the same
autoradiograph exposure and all lanes in (b) are from the same
autoradiograph exposure.
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Da, and the sequence contains one potential glycosylation
site (amino acids 172-175). Comparison of the ARA amino
acid sequence with protein databases showed the amino acid
sequence of MRP (171 562 Da unglycosylated) was the most
similar. A computer alignment of the amino acid sequence of
ARA and MRP is shown in Figure 3. The sequences have
51% amino acid identity and when conserved substitutions
were taken into account the sequences have 71% similarity.
Comparison of the ARA and MRP amino acid sequences
shows some regions of higher similarity. The region centred
around the Walker A site (Walker et al., 1982) has 17
identical amino acid residues and the region around the
Walker B (Walker et al., 1982) and the ABC signature (S)
(Higgins et al., 1990) sites have 30 out of 35 identical residues
with four of the five mismatches being conserved substitu-
tions. The identification of the highly conserved nucleotide
binding site and the similarity of ARA and MRP indicate
that ARA is a member of the ABC transporter family.
I
ARA 1 MALRGFCSRWLRPAhAIGLFASMAAVLLGGARASRLLFQRLLWDVVRSPI 50
MRP 1014 VRLSVYGA..LGISQGIAVFGYSM VSIGGILASRCLHVDLLHSILRSPM 1061
x
II
ARA 51 SFFERTPIGHLLNRFSKET1DTVDVDIPDKLRSLLM00GLLEVSLVVEWP 100
1111111 I1I1I1111 I1 l1111 I11 1 1
MRP 1062 SFFERTPSGNLVNRFSKELDTVDSMIPEVIKMFMGSLFNVIGACIVILLA 1111
XI
ARA 101
MRP 1112
TPL PLWPSCH ..... 110
TI: I::.16
TPIAAIIPPLGLIYFFVQRFYVASSRQLKRLESVSRSPVYSHFNETLLG 1161
III
ARA 111 ....... CFSSTLGFRWJpANVELLGNGLV 133
1. .1 : 12 1 11Q1 V1 1 l 1
MRP 1162 VSVIRAFEEQERFIHQSDLKVDENQKAYYPSIVANRWLAVRLECVGNCIV 1211
ARA 134
MRP 1212
ARA 184
MRP 1262
ARA 234
MRP 1312
ARA 284
MRP 1362
ARA 334
MRP 1412
ARA 384
MRP 1462
IV
FAAATCAVLSKAHLSAGLVGFSVSAALOVTOTLQWVVRNWTDLENSIVSV 183
:11 11 :1: 11 11 1 1 1:1 1 I11
LFALLFAVISRHSLSAGLVGLSVSYSLQVTTYLNWLVRMSSEMETNIVAV 1261
XII
ERMQDYAWTPKEAPWRLPTCAAQPPWPQGGQIEFRDFGLRYRPELPLAVQ 233
ERLKEYSETEKEAPWQIQETRPPSSWPQVGRVEFRNYCLRYREDLDFVLR 1311
GVSFKIHAGEKVGIVGRTGAGKSLASGLLRLQEAAEGGIWIDGVPIAHV 283
1 1111III1 IIIIIIII11 II.11 1 .I.111 1 111 :11.
HINVTINGGEKVGIVG&ALQSSLTLGLFRINESAEGEIIIDGINIAKI 1361
A
GVHTLRSRISIIPQDPILFPGSLRMNLDLLQEHSDEAIWAALETVQLKAL 333
GLHDLRFKITIIPQDPVLFSGSLRMNLDPFSQYSDEEVWTSLELAHLKDF 1411
VACLPGQLQYKCADRGEDLS QKOLLfLARALLRKTQOIUI1UEATAAVD 383
VSALPDKLDHECAEGGENL GQRLLCLARALLRKTKWILVLEATAAVD 1461
S B
V
PGTELQMOAMLGSWFAOCTVLLIAHRLRSVMDCARVLVMDKGQVAESGSP 433
LETDDLIQSTIRTQFEDCTVLTIAHRLNTIMDYTRVIVLDKGEIQEYGAP 1511
ARA 434 AQLLAQKGLFYRLAQESGLV 453
MRP 1512 SDLLQQRGLFYSMAKDAGLV 1531
Figure 3 Derived amino acid sequence of the anthracycline resistance-associated (ara) gene (EMBL accession code X95715) aligned
with the sequence of MRP (EMBL accession code L05628). The sequences are as aligned by the program bestfit. The Walker A and
B sites and the ABC signature site are underlined and labelled A, B and S respectively. Predicted transmembrane domains are
underlined and are numbered with roman numerals.
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Figure 4 Scale linear map of the functional regions of ARA and
MRP showing the relative position and number of ATP-binding
regions and the position and number of predicted transmembrane
regions.
A map of the characteristic functional regions of ABC
proteins (ATP-binding region and associated transmembrane
regions) for ARA and MRP is shown in Figure 4. ARA has
only one ATP-binding site while MRP has two. ARA has five
predicted transmembrane domains compared with the three
MRP domains in the related regions. As indicated on the
sequence in Figure 3 and shown graphically in Figure 4,
ARA site I lines up with MRP site X, and MRP site IX does
not have an equivalent in ARA. The next site for ARA (II)
corresponds to MRP site XI, and the third ARA site (III) is
closer than the next MRP site (XII) as there is an additional
67 amino acids in the sequence of MRP. ARA has two extra
regions, ARA sites IV and V. Using the same prediction
programme as was used for ARA, these sites are not
predicted to be present in MRP.
Discussion
In this report, we have described a novel protein that we have
named the anthracycline resistance-associated (ARA) protein.
Northern blot analysis showed that ara mRNA was
overexpressed in the MDR EIOOO subline compared with
the parent CEM cell line in which ara mRNA was below the
level of detection using Northern blot analysis of total RNA
(Figure 1). The mRNA for mrp is also overexpressed in the
E1000 subline (Figure 1; Davey et al., 1995). A basal level of
mrp mRNA can be detected in total RNA from the CEM
cells (Davey et al., 1995). The mechanism causing increased
expression of each of these genes is probably related to the
amplification of the genes in the E1000 subline relative to the
CEM line as evidenced by Southern blot analysis (Figure 2)
which shows that both are amplified to a similar extent.
Amplification of the mrp gene in MDR cell lines has been
previously reported (Cole et al., 1992).
Amino acid sequence comparisons indicate that ARA is a
member of the ABC protein family and it is most similar to
MRP (51% identical). ARA has similarity with numerous
other members of the large ABC protein family. Two such
proteins are the yeast proteins, YCF1 (EMBL accession
P39109; Szczypka et al., 1994) and YK84 (EMBL accession
P36171), each having 43% amino acid identity to ARA. The
similarity to YCF1 is perhaps more significant as there are 16
out of 17 identical residues centred around the Walker A site
and 27 out of 35 identical residues centred around the Walker
B and ABC signature sites. Thus ARA, MRP and YCF1
sequences are highly conserved in these regions, suggesting
that they may transport similar substrates. However, ARA
and MRP are both associated with MDR whilst YCF1 is
involved in cadmium resistance. The-primary substrate for
these proteins therefore appears to be diverse. However, it
may be that these proteins transport substrates with an
associated common factor. This may involve glutathione as
this is implicated in the MDR in the E1000 subline (Davey et
al., 1995) and can also be involved in heavy metal resistance
(Coblenz and Wolf, 1994).
An important feature of ABC proteins is the presence of
transmembrane regions. A comparison of the ARA
transmembrane regions with the region of similarity in
MRP shows ARA has one extra predicted transmembrane
region on the carboxy terminal side of the ATP-binding
region (region V, Figure 4). This region in MRP is not a
predicted transmembrane region. Some ABC proteins have
been reported which have the transmembrane regions on the
carboxy side of the ATP-binding region (Turi and Rose,
1995), but the ATP-binding region situated in the middle of
its associated transmembrane regions has not been previously
reported. However, it is not known if the extra regions in
ARA (IV and V) actually function as transmembrane regions
as they may be precluded from associating with the
membrane because of the surrounding protein secondary
structure.
Whilst ARA is related to MRP by amino acid sequence
comparison, a major difference between the two is the size of
the mRNA and of the putative proteins. Ara mRNA was
estimated to be 2.2 kb compared with mrp mRNA which is
6.6 kb (Figure 1). From the derived amino acid sequence, the
ARA protein would be 49.5 kDa without glycosylation, and
there is one potential glycosylation site located in a predicted
hydrophilic region. ARA is most similar to the carboxy half
of MRP, as shown in the aligned amino acid sequence
(Figure 3). ARA, having only one nucleotide binding site and
associated transmembrane regions, is different to most
mammalian ABC proteins which have two functional units
on a single polypeptide. Current knowledge of ABC proteins
indicates that ARA would have to act as a homodimer or as
a heterodimer with another ABC protein (Higgins, 1992).
One possibility could be an association between ARA and
MRP.
Whilst most mammalian ABC proteins reported have two
ATP-binding regions and associated transmembrane regions,
a number of proteins with a single ATP binding site and
associated transmembrane regions have been described, and
these are all organelle-associated. In humans, there are two
peroxisomal membrane ABC proteins, PMP70 (Kamijo et
al., 1992) and ALDP (Mosser et al., 1993), and two
endoplasmic reticular ABC proteins, TAPI and TAP2
(Beck et al., 1992). TAPI and TAP2 are involved in
peptide transport into the endoplasmic reticulum (ER)
(Kelly et al., 1992) for the export of peptide antigen/MHC
complex to the cell surface for recognition by cytotoxic T
cells. Increased TAP expression has been associated with
MRP-related MDR (Izquierdo et al., 1995). Whilst more
data are required to determine the function of ARA, an
interesting parallel with the TAP proteins can be drawn. In
the E1000 subline and other MRP-expressing cell lines, drug
transport via partitioning into the endoplasmic reticulum has
been hypothesised. Evidence has implicated conjugation of
drug to glutathione as part of this transport process
(Jedlitschky et al., 1994; Leier et al., 1994; Muller et al.,
1994); hence it may be that ARA is involved in transport of
a glutathione-drug conjugate across the endoplasmic
reticular membrane. MRP has been located in the ER
using a polyclonal antibody (Krishnamachary et al., 1994)
raised against the carboxy terminal 15 amino acids of MRP,
of which 9 out of the 15 are identical to ARA. Given these
similarities, it is possible that ARA was also detected in the
ER. This is supported by the report of a 45 kDa
deglycosylated protein being observed in the ER of MDR
cells, using this antibody (Krishnamachary et al., 1994).
In this report, we have identified the novel ABC protein
ARA, the mRNA for which is expressed in the MDR EIOOO
subline and was not detected in the parent CEM cell line. The
sequence similarity between ARA and MRP and their
elevated expression are consistent with ARA, as well as
MRP, being involved in the complex drug resistance
mechanisms in the E1000 subline. Evidence pointing to the
role of ARA in drug resistance includes overexpression of
lMrl2 ierminal t-uurt terminai
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ARA in the E1000 subline, the involvement of glutathione
metabolism in the MDR of the EIO1O subline and the
possible location of ARA in the ER membrane where it could
have a role in the transport of glutathionylated drug.
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